18. 脊髄小脳変性症（多系統萎縮症を除く。） Spinocerebellar degeneration Clinical trials / Disease details
臨床試験数 : 71 / 薬物数 : 99 - (DrugBank : 30) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01965327 (ClinicalTrials.gov) | August 2013 | 27/8/2013 | Interferon Gamma-1b in Friedreich Ataxia (FRDA) | Open-label Pilot Study of Interferon Gamma-1b (Actimmune™) for the Treatment of Friedreich Ataxia (FRDA) | Friedreich Ataxia | Drug: Interferon Gamma-1b | Children's Hospital of Philadelphia | Friedreich's Ataxia Research Alliance;Vidara Therapeutics Research Ltd | Completed | 5 Years | 17 Years | All | 12 | Phase 2 | United States |
| 2 | EUCTR2012-001881-14-IT (EUCTR) | 01/03/2013 | 11/01/2013 | A phase II clinical trial to evaluate the safety and efficacy of interferon gamma in elevating frataxin levels in Friedreich ataxia patients | A phase II clinical trial to evaluate the safety and efficacy of interferon gamma in elevating frataxin levels in Friedreich ataxia patients - GIFT/1 | Friedreich's Ataxia MedDRA version: 14.1;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: IMUKIN*SC 6F 0,5ML 100MCG INN or Proposed INN: INTERFERON GAMMA-1B | AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2 | Italy |